These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 23159849)

  • 1. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
    Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
    Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated estrogen receptor-α in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction.
    Jung YS; Chun HY; Yoon MH; Park BJ
    Neoplasia; 2014 Dec; 16(12):1070-81. PubMed ID: 25499220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
    Zhou L; Yang H
    PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WSB1 promotes tumor metastasis by inducing pVHL degradation.
    Kim JJ; Lee SB; Jang J; Yi SY; Kim SH; Han SA; Lee JM; Tong SY; Vincelette ND; Gao B; Yin P; Evans D; Choi DW; Qin B; Liu T; Zhang H; Deng M; Jen J; Zhang J; Wang L; Lou Z
    Genes Dev; 2015 Nov; 29(21):2244-57. PubMed ID: 26545811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F; Kentsis A; Osman R; Pan ZQ
    J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1alpha.
    André H; Pereira TS
    J Biol Chem; 2008 Oct; 283(43):29375-84. PubMed ID: 18694926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. USP9X destabilizes pVHL and promotes cell proliferation.
    Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
    Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VBP1 represses cancer metastasis by enhancing HIF-1α degradation induced by pVHL.
    Kim JA; Choi DK; Min JS; Kang I; Kim JC; Kim S; Ahn JK
    FEBS J; 2018 Jan; 285(1):115-126. PubMed ID: 29121446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.
    Foxler DE; Bridge KS; James V; Webb TM; Mee M; Wong SC; Feng Y; Constantin-Teodosiu D; Petursdottir TE; Bjornsson J; Ingvarsson S; Ratcliffe PJ; Longmore GD; Sharp TV
    Nat Cell Biol; 2012 Jan; 14(2):201-8. PubMed ID: 22286099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
    Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
    PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
    He X; Wang J; Messing EM; Wu G
    Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.
    Merlo A; Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Pitiot AS; Balbín M; Astudillo A; Valdés N; Scola B; Del Toro R; Méndez-Ferrer S; Piruat JI; Suarez C; Chiara MD
    Oncotarget; 2017 Jan; 8(4):6700-6717. PubMed ID: 28036268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
    J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.
    Frost J; Rocha S; Ciulli A
    J Biol Chem; 2021 Aug; 297(2):100910. PubMed ID: 34174286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.
    Okumura F; Uematsu K; Byrne SD; Hirano M; Joo-Okumura A; Nishikimi A; Shuin T; Fukui Y; Nakatsukasa K; Kamura T
    Mol Cell Biol; 2016 Jun; 36(12):1803-17. PubMed ID: 27090638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.